UPDATE 1-China Nuokang shares fall in Nasdaq debut

* Shares down about 6 pct from $9 IPO price

* Sold 5 mln ADS shares, raised about $45 mln

NEW YORK Dec 10 (Reuters) - Shares of China Nuokang Bio-Pharmaceutical Inc fell about 6 percent in early trades on its Nasdaq debut on Thursday.

The Shenyang, China-based bio-pharmaceutical company on Wednesday sold 5 million American Depositary Shares for $9 a piece, raising about $45 million. The company had expected the shares to sell for between $10 and $12, each.

China Nuokang develops, manufactures and sells blood- and heart-related products, including those that control bleeding and irregular heartbeats. It said it plans to use proceeds from the offering to fund research and development, expansion, and general corporate purposes.

Shareholders in the company include Anglo China Bio-technology Investment Holdings Limited, Sequoia Capital China Growth Fund and affiliated funds, Britain Ukan Technology Investment Holdings (Group) Limited and HBM BioMed China. Britain Ukan and HBM BioMed China are each selling part of their stake in the company.

The company reported revenues of 200 million yuan ($29 million) in the nine months ended Sept 30, up 30.3 percent from a year ago. The company reported net income of 41.64 million yuan compared with 41.72 million yuan in the year ago period.

Underwriters for the offering, who have the option to purchase an additional 750,000 American Depositary Shares, are led by Jeffries & Co.

(Reporting by Clare Baldwin; editing by Gunna Dickson)